PDF(Pubmed)
Abstract：
BACKGROUND: Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder of the gastrointestinal system. So far, no treatment has been identified that can completely cure IBD. Lactobacillus brevis is hypothesized to be beneficial in preventing inflammation. This study aimed to evaluate the potential probiotic effects of live and pasteurized L. brevis IBRC-M10790 on the in vitro cell co-culture model of IBD.
METHODS: An in vitro intestinal model was established using a transwell co-culture system of Caco-2 intestinal epithelial cells and RAW264.7 macrophages. Inflammatory conditions were induced in RAW264.7 cells using lipopolysaccharide. The effects of live and pasteurized L. brevis IBRC-M10790 on inflammatory mediators and epithelial barrier markers were investigated.
RESULTS: L. brevis IBRC-M10790 was able to significantly decrease the proinflammatory cytokines (IL-6, IL-1β, and TNF-α) and increase the anti-inflammatory cytokine (IL-10) in the in vitro co-culture system. In addition, L. brevis increased adherens and tight junction (TJ) markers (ZO-1, E-cadherin, and Occludin) in Caco-2 intestinal epithelial cells. Based on the results, pasteurized L. brevis showed a higher protective effect than live L. brevis.
CONCLUSIONS: Our findings suggest that live and pasteurized forms of L. brevis possess probiotic properties and can mitigate inflammatory conditions in IBD.
METHODS: An in vitro intestinal model was established using a transwell co-culture system of Caco-2 intestinal epithelial cells and RAW264.7 macrophages. Inflammatory conditions were induced in RAW264.7 cells using lipopolysaccharide. The effects of live and pasteurized L. brevis IBRC-M10790 on inflammatory mediators and epithelial barrier markers were investigated.
RESULTS: L. brevis IBRC-M10790 was able to significantly decrease the proinflammatory cytokines (IL-6, IL-1β, and TNF-α) and increase the anti-inflammatory cytokine (IL-10) in the in vitro co-culture system. In addition, L. brevis increased adherens and tight junction (TJ) markers (ZO-1, E-cadherin, and Occludin) in Caco-2 intestinal epithelial cells. Based on the results, pasteurized L. brevis showed a higher protective effect than live L. brevis.
CONCLUSIONS: Our findings suggest that live and pasteurized forms of L. brevis possess probiotic properties and can mitigate inflammatory conditions in IBD.
摘要：
背景：炎症性肠病（IBD）是一种慢性，胃肠道系统复发性炎性疾病。到目前为止,目前尚无可完全治愈IBD的治疗方法.据推测,短乳杆菌有益于预防炎症。本研究旨在评估活的和巴氏灭菌的短乳杆菌IBRC-M10790对IBD的体外细胞共培养模型的潜在益生菌作用。
方法：使用Caco-2肠上皮细胞和RAW264.7巨噬细胞的transwell共培养系统建立体外肠模型。使用脂多糖在RAW264.7细胞中诱导炎性病症。研究了活的和巴氏灭菌的短乳杆菌IBRC-M10790对炎症介质和上皮屏障标志物的影响。
结果：L.brevisIBRC-M10790能够显着降低促炎细胞因子（IL-6，IL-1β，和TNF-α），并增加体外共培养系统中的抗炎细胞因子（IL-10）。此外,短乳杆菌增加粘附和紧密连接（TJ）标记（ZO-1，E-钙粘蛋白，和occludin）在Caco-2肠上皮细胞中。根据结果,巴氏杀菌短乳杆菌比活短乳杆菌显示出更高的保护作用。
结论：我们的研究结果表明，活的和巴氏杀菌形式的短乳杆菌具有益生菌特性，可以减轻IBD的炎症。
方法：使用Caco-2肠上皮细胞和RAW264.7巨噬细胞的transwell共培养系统建立体外肠模型。使用脂多糖在RAW264.7细胞中诱导炎性病症。研究了活的和巴氏灭菌的短乳杆菌IBRC-M10790对炎症介质和上皮屏障标志物的影响。
结果：L.brevisIBRC-M10790能够显着降低促炎细胞因子（IL-6，IL-1β，和TNF-α），并增加体外共培养系统中的抗炎细胞因子（IL-10）。此外,短乳杆菌增加粘附和紧密连接（TJ）标记（ZO-1，E-钙粘蛋白，和occludin）在Caco-2肠上皮细胞中。根据结果,巴氏杀菌短乳杆菌比活短乳杆菌显示出更高的保护作用。
结论：我们的研究结果表明，活的和巴氏杀菌形式的短乳杆菌具有益生菌特性，可以减轻IBD的炎症。
